■ 英語タイトル：Human Microbiome Market Report 2023-2033 : Forecasts by Product (Prebiotics, Medical Drugs, Diagnostic Tests, Skin Products), by Type (Fecal Microbiota Transplant, Live Biotherapeutics Products (LBP), Prebiotics, Post-Biotics, Precision Antibiotics), by Technology (Proteomics, Metabolomics, Genomics (16srRNA Sequencing, Shotgun Sequencing and Long Read Metagenomics)), by Application (Gastrointestinal, Infectious Diseases, Metabolic Diseases, Cancers, Gut-Brain Axis, Others ) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

■ 発行会社/調査会社：visiongain ■ 商品コード：VGA23FB016 ■ 発行日：2023年1月30日 ■ 調査対象地域：グローバル ■ 産業分野：医薬品 ■ ページ数：281 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後24時間以内）

The Human Microbiome Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Big Pharma Players Striving To Gain Market Entry Through Collaboration with Microbiome Players
There has been a growing interest from the big pharma players in microbiome research. Many of the big pharma players have been supporting the start-up microbiome players for their clinical drug candidate through funding and collaborations. For instance, in July 2022, Enterome a clinical stage microbiome company signed a strategic R&D collaboration with Nestle Health Science. This license agreement primarily targeted food allergy and Inflammatory Bowel Disease (IBD) under this agreement Enterome will receive an upfront payment of €40 million (US$46.9 million) in cash and equity. In return, Nestle Health Science will be eligible to receive the royalties and sales milestone payments on commercialization of the drug candidates. In February 2021, 4D Pharma Inc. has collaborated with Merck Co Ltd. and Pfizer for its oncology and vaccines to evaluate its MRx5018 in combination with BAVENCIO for treatment of locally advanced or metastatic urothelial carcinoma. Both Merck KGaA and Pfizer Inc. will co-develop and also commercialize it in collaboration. Similarly, in January 2021, Vedanta Biosciences has received US$25 million investment fund from Pfizer as a part of breakthrough growth initiative. Vedanta will use these funds for Phase II study of VE202 indicated for treatment of Inflammatory Bowel Disease. In July 2021, Seres announced its collaboration with Nestle Health Science to co-commercialize SER-109 therapeutic drug for treatment of Clostridioides difficile infection (CDI) in U.S. and Canada. In 2019, Seres had collaborated with AstraZeneca and received US$20 million as a financial support to conduct its research activity for immuno-oncology therapies. With more pharma players are entering this market, the overall market for human microbiome is expected to foresee a staggering growth during the forecast period.

Regulatory Approvals to Challenge Market Growth
The human microbiome has a huge potential in curing and treating diseases that have been difficult to treat through conventional methods. Moreover, the use of Live Biotherapeutic Products (LBPs) has been studied to be of great potential, however lack of defined regulatory approvals for human microbiomes is hampering the growth of this market. There has not been any clearly defined segregation for LBPs and their use, especially when classifying prebiotics, probiotics, and pharmaceutical products. The U.S. FDA in 2010, first time presented draft guidance for microorganisms intended to prevent and treat diseases which got updated in 2016 to officially make a category for LBPs. Similarly, the European Pharmacopeia Commission issued a draft in 2019 with a mention of LBPs to comply with the legislation of biological medicinal products with additional specific guidelines for LBPs. There has been a clear demand from the regulatory authorities regarding the benefits against the risks of LBPs. Conventional GMP practices emphasize the removal of microbes in the final product however, human microbiome products need to be in the final product. Hence, drafting new guidelines for regulatory approvals needs detailed documentation and justification as these products differ from non-therapeutic products. Risk assessment through genomic profiling is crucial as the LBPs have the potential to transfer genes to other microbes or may metabolize other drugs or hormones in the body. To avoid this, in vitro and ex-vivo studies, and animal models studies are essential. Detailed documentation of the origin of the strain, isolation procedure, and cell banking is required. In addition, the difficulty in having consistent batches of LBPs is also a major GMP regulatory hurdle. We believe, that as the market expands there will be well-defined regulatory guidelines for conducting human microbiome studies, at present the approval process poses a major challenge for the market players of this segment.

What Questions Should You Ask before Buying a Market Research Report?
• How is the human microbiome market evolving?
• What is driving and restraining the human microbiome market?
• How will each human microbiome submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each human microbiome submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading human microbiome market broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the human microbiome drug pipeline status for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of human microbiome market projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the human microbiome market?
• Where is the human microbiome market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the human microbiome market today, and over the next 10 years:
• Our 281-page report provides 121 tables and 168 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the human microbiome market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

By Therapeutics
• Gastrointestinal Disorders
• Infectious Diseases
• Metabolic Disorders
• Cancers
• Gut-Brain Axis
• Others

By Type
• Fecal Microbiota Transplant (FMT)
• Live Biotherapeutic Product (LBP)
• Prebiotics
• Post-Biotics
• Precision Antibiotics

By Product
• Prebiotics & Probiotics
• Medicinal Drugs
• Diagnostic Tests
• Skin Microbiome

By Technology
• Genomics
– 16SrRNA Amplicon Sequencing
– Shotgun Metagenomic Sequencing
– Longread Metagenomic Sequencing
• Proteomics
• Metabolomics

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• South Korea
• Taiwan
• Rest of Asia

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• Saudi Arabia
• South Africa
• UAE
• Rest of Middle East & Africa

The report also includes profiles and for some of the leading companies in the Human Microbiome Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• 4D Pharma Plc.
• Axial Therapeutics
• BiomX
• Enterobiome
• Enterome
• Finch Therapeutics Group Inc.
• MaaT Pharma
• Rebiotix Inc.,( a Ferring Pharmaceutical Company)
• Second Genome
• Seres Therapeutics
• Synlogic
• Theriva Biologics (ex-Synthetic Biologics)
• Vedanta Biosciences Inc.

Overall world revenue for Human Microbiome Market, 2023 to 2033 in terms of value the market will surpass US$224 million in 2023, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Human Microbiome Market, 2023 to 2033 report help you?
In summary, our 280+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Human Microbiome Market, 2023 to 2033 Market, with forecasts by therapeutics, type, product, technology and company size, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 21 key national markets – See forecasts for the Human Microbiome, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Taiwan among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 13 of the major companies involved in the Human Microbiome Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Human Microbiome Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

■ 英語タイトル：Allergic Rhinitis Drugs Market Report 2023-2033 : Forecasts by Treatment (Antihistamines, Immunotherapy (SCIT, SLIT), Corticosteroids, Decongestants, Others), by Disease (Seasonal Allergic Rhinitis, Perennial Allergic Rhinitis, Occupational Allergic Rhinitis), by Route of Administration (Oral, Nasal, Intraocular, Intravenous), by Distribution Channel (Retail Pharmacies, Hospital Pharmacies, Online Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

■ 発行会社/調査会社：visiongain ■ 商品コード：VGA23FB015 ■ 発行日：2023年1月30日 ■ 調査対象地域：グローバル ■ 産業分野：医薬品 ■ ページ数：269 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後24時間以内）

The Allergic Rhinitis Drugs Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Advent of Innovative Intranasal Therapies for Treatment of Allergic Rhinitis
Intranasal therapies are gaining acceptance owing to their better safety and efficacy. This route of administration is also recommended by physicians and allergists since they do not have any systemic side-effects and their adequate concentrations can be achieved at receptor sides in nasal mucosa. Their adverse effects are limited to dryness, sneezing and stinging of nasal mucosa. Several companies are developing innovative intranasal drugs owing to their inherent advantages over other routes of administration. For instance, ClorNasal™ developed by Dr. Ferrer BioPharma is recognized as the best intranasal pharmacological formulation in the world. It is used in the treatment of several ailments including allergic rhinitis, Respiratory Syncytial Virus (RSV) Infection and COVID-19. Similarly, Altamira Therapeutics Ltd. Developed the nasal spray Bentrino. It prevents the onset of allergic symptoms by airborne allergens such as dust mites, and pollens.

Similarity of Symptoms With Other Diseases
Allergic rhinitis is an infection caused due to allergic reaction of immune system to an allergen. Some of the most common symptoms of allergic rhinitis include stuffy nose, watery eyes, itchy mouth, sneezing, post-nasal drip, sore throat, facial pain or pressure, partial loss of hearing, smell, and taste, and fatigue among others. The symptoms are very similar to cold and cough which might be caused by virus and not by any of the agents that cause allergies. The allergies can also trigger other conditions such as asthma, sinusitis, otitis media or eczema if not treatment well in time. Selection of the right drug candidate remains a major problem in the absence of accurate diagnosis. Administration of immunotherapy or allergy shots may have serious side effects such as hives and rash. It may sometimes have dangerous side effects such as anaphylaxis which may require years of treatment.

Adverse Effects of Drugs Used in Allergic Rhinitis Treatment
Allergic medications are mostly used over a long period of time to keep the lifestyle unaffected by different types of allergens in the environment. Antihistamines are the most widely used drug type for treatment of allergic infections. Some of the short-term side-effects of antihistamines include constipation, urinary retention, dry mouth, enhanced appetite, and worsen narrow-angle glaucoma. Several side-effects of nasal decongestants include high blood pressure, irritability, headache, and sleeplessness. Topical corticosteroids cause absorption of the drug into the systemic circulation which has potential to cause disturbance to the normal hormonal levels in the body. Corticosteroid ocular solutions can cause glaucoma, cataract and other eye infections. Intranasal corticosteroids can irritate nasal mucosa and also affect the cell lining of mouth and throat make them dry and soar. Oral corticosteroids are associated with side-effects such as osteoporosis, stomach ulceration, hyperglycaemia, increased blood pressure and muscle weakness.

What Questions Should You Ask before Buying a Market Research Report?
• How is the Allergic Rhinitis Drugs Market evolving?
• What is driving and restraining the Allergic Rhinitis Drugs Market?
• How will each Allergic Rhinitis Drugs submarket grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each Allergic Rhinitis Drugs submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading Allergic Rhinitis Drugs Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Allergic Rhinitis Drugs development projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of Allergic Rhinitis Drugs development projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Allergic Rhinitis Drugs Market?
• Where is the Allergic Rhinitis Drugs Market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Allergic Rhinitis Drugs Market today, and over the next 10 years:
• Our 269-page report provides 105 tables and 173 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Allergic Rhinitis Drugs Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising prices of allergic rhinitis drugs and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Treatment Type
• Antihistamines
• Immunotherapy
– Subcutaneous Immunotherapy (SCIT)
– Sublingual Immunotherapy (SLIT)
• Corticosteroids
• Decongestants
• Others

Disease Type
• Seasonal Allergic Rhinitis
• Perennial Allergic Rhinitis
• Occupational Allergic Rhinitis

Route of Administration
• Oral
• Nasal
• Intraocular
• Intravenous

Distribution Channel
• Retail Pharmacies
• Hospital Pharmacies
• Online channels

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 16 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Allergic Rhinitis Drugs Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• Alcon
• AstraZeneca
• Bayer AG
• Dr Reddy’s Laboratories
• GlaxoSmithKline PLC
• Johnson & Johnson
• Merck & Co
• Sanofi S.A.
• Sun Pharmaceuticals
• Teva Pharmaceutical Industries Ltd

Overall world revenue for Allergic Rhinitis Drugs Market, 2023 to 2033 in terms of value the market will surpass US$12,410 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Allergic Rhinitis Drugs Market, 2023 to 2033 report help you?
In summary, our 260+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Allergic Rhinitis Drugs Market, 2023 to 2033 Market, with forecasts for Type of Treatment, Disease, Route of Administration and Distribution channel at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 16 key national markets – See forecasts for the Allergic Rhinitis Drugs Market, 2023 to 2033 market in North America, Europe, Asia-Pacific and Latin America and Middle East and Africa. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles of the major companies involved in the Allergic Rhinitis Drugs Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Allergic Rhinitis Drugs Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

■ 英語タイトル：Biodefence Market Report 2023-2033 : Forecasts by Product (Vaccines (Anthrax, Smallpox, Botulism), Biothreat Detection Devices (Assays and Reagents, Detectors, Identifiers, Samplers)) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis
	■ 発行会社/調査会社：visiongain ■ 商品コード：VGA23FB004 ■ 発行日：2023年1月13日 ■ 調査対象地域：グローバル ■ 産業分野：医薬品 ■ ページ数：197 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後24時間以内）

The Biodefence Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing R&D Investments in Developed Countries
Growing R&D investments enable pharmaceutical and biopharmaceutical companies to manufacture superior quality and technologically advanced bio-threat detection devices that should significantly impact the industry growth. Furthermore, European government also supports the R&D activities to manufacture vaccines against various diseases such as anthrax, small pox and botulism in large batches to fight infections and prevent the spread of endemic diseases. Bioterrorism attacks lead to deaths and may weaken the economy hence, government funds various pharmaceutical as well as biopharmaceutical companies that will elevate the industry growth in foreseeable future.

Increasing Awareness Regarding Bioterrorism Attacks to Propel Industry Growth
Increasing awareness regarding bioterrorism attacks in developed as well as underdeveloped economies will significantly fuel the biodefence market growth over the forecast period. Owing to the advent of internet and growing adoption of social media, news about the biological warfare in any part of the world can spread across the globe. It can cause anxiety to people located faraway and can greatly impact trade and travel. Governments in the developing countries such as Japan and India plan public awareness campaigns to raise public awareness about bioterrorism attacks. Such preventive measures undertaken by the government to combat various endemic diseases will boost industry growth in the foreseeable future.

Low Government Funding in Underdeveloped Regions Likely to Challenge Market Growth
Minimal government intervention and low R&D funding in underdeveloped regions will impede the biodefence market growth over the forecast period. Furthermore, due to poor economic development, governments and regulatory authorities in countries such as Mexico and Brazil are unable to make significant investments to promote the use of biothreat detection devices. There is a lack of awareness in developing regions about the availability of technologically advanced biothreat detection devices. Additionally, there is no established regulatory framework for biodefence devices and vaccines in underdeveloped economies. Key players that operate in the biodefence industry find it difficult to enter these countries due to changing trade policies. As a result, the distribution of tools and vaccinations used to combat bioterrorism is low in emerging regions which may hamper the Biodefence market growth.

What Questions Should You Ask before Buying a Market Research Report?
• How is the Biodefence Market evolving?
• What is driving and restraining the Biodefence Market?
• How will each Biodefence submarket grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each Biodefence submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading Biodefence Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Biodefence development projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of Biodefence development projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Biodefence Market?
• Where is the Biodefence Market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Biodefence Market today, and over the next 10 years:
• Our 197-page report provides 112 tables and 107 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Biodefence Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising prices of bio-threat detection devices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

By Product
• Vaccines
– Anthrax
– Small Pox
– Botulism
– Others
• Biothreat detection devices
– Assays and reagents
– Detectors
– Identifiers
– Samplers

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 16 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Biodefence Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• Alexeter Technologies, LLC,
• Altimmune
• Achaogen, Inc.
• Alnylam Pharmaceuticals
• ANP Technology
• Bavarian Nordic
• BBI Detection
• Biofire Defense (bioMerieux SA)
• Biosearch Technologies
• Bruker
• Dynport Vaccine Company
• Electronic Sensor Technology Inc.
• Elusys Therapeutics
• Emergent BioSolutions Inc.
• Ichor Medical
• NanoLogix
• New Horizons Diagnostic Corporation
• PositiveID Corporation
• Research International
• SIGA Technologies, Inc.
• Statera Biopharma (Cleveland Biolabs)
• Smith’s Detection
• Synexis Systems

Overall world revenue for Biodefence Market, 2023 to 2033 in terms of value the market will surpass US$15,922 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Biodefence Market, 2023 to 2033 report help you?
In summary, our 197-page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Biodefence Market, 2023 to 2033 Market, with forecasts for Type of Product, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 16 key national markets – See forecasts for the Biodefence Market, 2023 to 2033 market in North America, Europe, Asia-Pacific and Latin America and Middle East and Africa. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles of the major companies involved in the Biodefence Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Biodefence Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

■ 英語タイトル：Neurotech Devices Market Report 2023-2033 : Forecasts by Product Type (Neurostimulation (Deep Brain Stimulator, Gastric Electric Stimulator, Spinal Cord Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Transcutaneous Electrical Nerve Stimulation (TENS), Others), Neuroprostheses, Neurosensing, Neurorehabilitation), by Conditions (Pain Management, Cognitive Disorders, Epilepsy, Urinary and Fecal Incontinence, Hearing Conditions, Parkinson’s Disease, Depression, Sleep Disorders, Essential Tremor, Other), by End-use (Hospitals, Ambulatory Surgical Centers, Homecare Facilities, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

■ 発行会社/調査会社：visiongain ■ 商品コード：VGA23FB010 ■ 発行日：2023年1月12日 ■ 調査対象地域：グローバル ■ 産業分野：医薬品 ■ ページ数：330 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後24時間以内）

The Neurotech Devices Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or expand their existing operations in a new region.

Growing Number of Elderly Populations with Neurological Disorders
The rapidly growing ageing population base suffering from neurological diseases will be a pivotal factor driving the market growth. Neurological disorders such as Alzheimer’s, dementia, Parkinson’s disease and chronic back & limb pain are most likely to affect people after 65 years of age. In such conditions using neurotech device therapies plays a pivotal role in treating these disorders. For instance, spinal cord stimulation (SCS) is an effective treatment for chronic back & limb pain. Also, failed back surgery syndrome (FBSS), peripheral neuropathic pain and residual pain after joint replacement in the elderly can be treated with spinal cord stimulators. The rising geriatric population will create such scenarios for market expansion.

Lack of Resources Serving to the Needs of Patients with Neurological Disorders
Lack of skilled healthcare practitioners and availability of high-technology equipment is anticipated to hamper market growth over the forecast period. Furthermore, inadequate access to universal mental healthcare services will pose as a major challenge for market expansion. The shortage of critical resources is grave in underdeveloped regions and neglected groups that do not have access to new treatment options and improved technologies. In most of the low and middle-income countries, there is shortage of skilled healthcare staff and basic neurological diagnostic services. Lack of authentic information and switching to alternative forms of treatment options delay the treatment.

What Questions Should You Ask before Buying a Market Research Report?
• How is the Neurotech Devices Market evolving?
• What is driving and restraining the Neurotech Devices Market?
• How will each Neurotech Devices submarket grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each Neurotech Devices submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading Neurotech Devices Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Neurotech Devices development projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of Neurotech Devices development projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Neurotech Devices Market?
• Where is the Neurotech Devices Market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Neurotech Devices Market today, and over the next 10 years:
• Our 330-page report provides 131 tables and 182 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Neurotech Devices Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, the impact of rising neurotech devices prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

By Product
• Neurostimulation
– Deep Brain Stimulator
– Gastric Electric Stimulator
– Spinal Cord Stimulator
– Sacral Nerve Stimulator
– Vagus Nerve Stimulator
– Transcutaneous Electrical Nerve Stimulation
• Neuroprostheses
• Neurosensing
• Neurorehabilitation

By Conditions
• Pain Management
• Cognitive Disorders
• Epilepsy
• Urinary and Fecal Incontinence
• Hearing Conditions
• Parkinson’s Disease
• Depression
• Sleep Disorders
• Essential Tremor
• Others

By End-use
• Hospitals
• Ambulatory Surgical Centers
• Homecare Facilities
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 16 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Neurotech Devices Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• Abbott Laboratories
• Advanced Bionics AG (Sonova)
• Boston Scientific Corporation
• BrainCo, Inc
• Cochlear Limited
• ElectroCore Inc
• Helbling Holding AG
• Innovative Health Solutions, Inc
• LivaNova PLC
• Medtronic
• MicroTransponder
• Natus medical Incorporated
• Neuronetics, Inc.
• Nihon Kohden Corporation
• Parasym Ltd.
• Synapse Biomedical
• tVNS Technologies GmbH (Cerbomed)

Overall world revenue for Neurotech Devices Market, 2023 to 2033 in terms of value the market will surpass US$13,102.0 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Neurotech Devices Market, 2023 to 2033 report help you?
In summary, our 330-page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Neurotech Devices Market, 2023 to 2033 Market, with forecasts for product, conditions, end-use, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 16 key national markets – See forecasts for the Neurotech Devices Market, 2023 to 2033 market in North America, Europe, Asia-Pacific and Latin America and Middle East and Africa. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles of the major companies involved in the Neurotech Devices Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Neurotech Devices Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

■ 英語タイトル：Asthma & COPD Therapies Market Report 2023-2033 : Forecasts by Product (Anti-inflammatory Drugs, Bronchodilators Monotherapy, Combination Drugs), by Route of Administration (Oral, Inhaled, Others), by Point of Sale (Retail Pharmacies, Hospital Pharmacies, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

■ 発行会社/調査会社：visiongain ■ 商品コード：VGA23FB019 ■ 発行日：2023年1月3日 ■ 調査対象地域：グローバル ■ 産業分野：医薬品 ■ ページ数：248 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後24時間以内）

The Asthma & COPD Therapies Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Expansion into Emerging Markets to Offer Lucrative Growth Opportunities
For the overall asthma and COPD market, expansion into the emerging markets will be of high importance in the years to come, in particular as the US and European markets become saturated and experience slow growth or decline due to patent expiry, generic competition and low healthcare budgets. The economic troubles currently being experienced in a number of emerging markets are likely to lift over the next ten years, returning those nations to continued expansion of their healthcare systems and satisfaction of unmet treatment needs. Inhaled drugs will continue to be less affected by patent expiries, as long as the inhaler patents are intact. Advances in inhaler design will continue to be of vital importance to the market.

Nevertheless, the asthma and COPD market have a potential for a number of blockbuster drugs with increasingly segmented sub-groups of patients. The market also benefits from increasing prevalence of respiratory diseases, coupled with the high economic cost of those diseases, revenues are expected to increase in the years to come. New combination drugs will drive growth. The industry will also have more biologics and synthetic anti-inflammatory agents for both asthma and COPD, as companies look to identify and offer treatments for multiple patient sub-groups. Future success will on long-term planning, to maximise the revenues for existing drugs (life cycle management), to successfully expand into emerging markets and to identify and address unmet needs in the patient population depend on novel and effective therapies.

What Questions Should You Ask before Buying a Market Research Report?
• How is the asthma & COPD therapies market evolving?
• What is driving and restraining the asthma & COPD therapies market?
• How will each asthma & COPD therapies submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each asthma & COPD therapies submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading asthma & COPD therapies markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the asthma & COPD therapies projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of
asthma & COPD therapies projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the asthma & COPD therapies market?
• Where is the asthma & COPD therapies market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the asthma & COPD therapies market today, and over the next 10 years:
• Our 248-page report provides 107 tables and 130 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the asthma & COPD therapies market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Product
• Anti-inflammatory Drugs
• Bronchodilators Monotherapy
• Combination Drugs

Route of Administration
• Oral
• Inhaled
• Others

Point of Sale
• Retail Pharmacies
• Hospital Pharmacies
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 20 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Italy
• Spain
• Rest of Europe

Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Asthma & COPD Therapies Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• AstraZeneca
• Boehringer Ingelheim
• Chiesi Farmaceutici S.p.A.
• Cipla Inc.
• F. Hoffmann-La Roche Ltd.
• Grifols S.A.
• GSK plc
• Mundipharma
• Novartis AG
• Pulmatrix
• Respiratorius AB
• Sanofi SA
• Sunovion Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.
• TFF Pharmaceuticals, Inc.
• Transpire Bio
• Verona Pharma plc
• Viatris Inc.

Overall world revenue for Asthma & COPD Therapies Market, 2023 to 2033 in terms of value the market will surpass US$47 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Asthma & COPD Therapies Market, 2023 to 2033 report help you?
In summary, our 240+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Asthma & COPD Therapies Market, 2023 to 2033 Market, with forecasts for Product, Route of Administration, and Point of Sale, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 20 key national markets – See forecasts for the Asthma & COPD Therapies Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 18 of the major companies involved in the Asthma & COPD Therapies Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Asthma & COPD Therapies Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

■ 英語タイトル：Wearable Brain Devices Market Report 2023-2033 : Forecasts by Product Type (Conventional Devices, Implantable Devices), by Technology (Vagus Nerve Stimulation (VNS), Responsive Neurostimulation, Deep Brain Stimulation), by Channel Type (32-Channel Type, 12-Channel Type, 14-Channel Type, Multi-channels), by End-user (Hospitals & Clinics, Neurology Centers, Homecare Settings, Intensive Care Units, Other), by Medical Setting (Epilepsy, Sleep Disorders, Parkinson’s Disease, Traumatic Brain Injury (TBI), Alzheimer's, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

■ 発行会社/調査会社：visiongain ■ 商品コード：VGA23FB011 ■ 発行日：2023年1月3日 ■ 調査対象地域：グローバル ■ 産業分野：医薬品 ■ ページ数：308 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後24時間以内）

The Wearable Brain Devices Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Market Is Expected to Rise as More People Develop Neurological Conditions
The market is expected to rise as more people develop neurological conditions such epilepsy, Parkinson’s disease, and Alzheimer’s disease. Other important drivers supporting the market’s expansion are the Asia Pacific region’s rapidly expanding elderly population, particularly in nations like Japan, India, and China, as well as speedy technology advancements. The ability to research the brain and assist in the treatment of many brain ailments and diseases has been made possible by contemporary technical breakthroughs in portable technologies.

The cost of brain dysfunction and neurological diseases is predicted to rise steadily over time, as is the demand for medical resources. Thanks to recent advancements in brain imaging technology, the brain and its functions may now be seen in high detail. For instance, near-infrared functional spectroscopy is a non-invasive imaging method that makes use of variations in haemoglobin light absorption patterns to estimate the relative concentration of haemoglobin in the brain. A rising market for such devices is a fact due to the frequency of neurological illnesses, the development of technology, concurrent increases in stress, and changes in lifestyle.

What Questions Should You Ask before Buying a Market Research Report?
• How is the wearable brain devices market evolving?
• What is driving and restraining the wearable brain devices market?
• How will each wearable brain devices submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each wearable brain devices submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading wearable brain devices markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the wearable brain devices projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of wearable brain devices projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the wearable brain devices market?
• Where is the wearable brain devices market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the wearable brain devices market today, and over the next 10 years:
• Our 308-page report provides 144 tables and 183 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the wearable brain devices market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising wearable brain devices prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Market Segment by Product Type
• Conventional Devices
• Implantable Devices

Market Segment by Technology
• Vagus Nerve Stimulation (VNS)
• Responsive Neurostimulation
• Deep Brain Stimulation

Market Segment by Channel Type
• 32-Channel Type
• 12-Channel Type
• 14-Channel Type
• Multi-channels

Market Segment by End-user
• Hospitals & Clinics
• Neurology Centers
• Homecare Settings
• Intensive Care Units
• Other End-user

Market Segment by Medical Setting
• Epilepsy
• Sleep Disorders
• Parkinson’s Disease
• Traumatic Brain Injury (TBI)
• Alzheimer
• Other Medical Setting

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• Spain
• United Kingdom
• France
• Italy
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Middle East & Africa
• GCC
• South Africa
• Rest of Middle East & Africa

Latin America
• Brazil
• Mexico
• Rest of Latin America

The report also includes profiles and for some of the leading companies in the Wearable Brain Devices Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• Advanced Brain Monitoring
• Cadwell Industries
• Compumedics, Ltd.
• Edwards Lifesciences Corporation
• GE Healthcare
• Koninklijke Philips N.V.( Philips Healthcare)
• Masimo Corporation
• Medtronic plc
• Nihon Kohden Corporation
• Siemens Healthineers

Overall world revenue for Wearable Brain Devices Market, 2023 to 2033 in terms of value the market will surpass US$303.6 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Wearable Brain Devices Market, 2023 to 2033 report help you?
In summary, our 300+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Wearable Brain Devices Market, 2023 to 2033 Market, with forecasts for product type, technology, channel type, end-user, medical setting and company size, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for four regional and 20 key national markets – See forecasts for the Wearable Brain Devices Market, 2023 to 2033 market in North America, Europe, Asia-Pacific and Latin America, and Middle East & Africa. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 10 of the major companies involved in the Wearable Brain Devices Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Wearable Brain Devices Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

■ 英語タイトル：Point of Care Diagnostics Market Report 2023-2033 : Forecasts by Product (Glucose Monitoring, Cardiometabolic Monitoring, Infectious Disease Testing, Coagulation Monitoring, Pregnancy & Fertility Testing, Tumor/Cancer Marker Testing, Urinalysis Testing, Cholesterol Testing, Hematology Testing, Drugs-of-abuse Testing, Fecal Occult Testing, Other), by Mode (Prescription-based, OTC), by Sample (Blood, Nasal and Oropharyngeal Swabs, Urine, Other), by Platform (Lateral Flow Assay, Dipstick, Microfluidics, Molecular Diagnostics, Immunoassay), by End-user (Clinics, Hospitals, Home Care Setting, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

■ 発行会社/調査会社：visiongain ■ 商品コード：VGA23FB007 ■ 発行日：2023年1月3日 ■ 調査対象地域：グローバル ■ 産業分野：医薬品 ■ ページ数：352 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後24時間以内）

The Point of Care Diagnostics Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Increasing Incidence of Target Conditions and Rising Number of CLIA Waived POC Tests Are Driving the Market Growth
Target conditions for POC testing are illnesses or disorders that require ongoing monitoring, such as diabetes, hemophilia, cancer, and cardiac problems. The adoption of POC testing equipment can therefore be attributed in large part to the rising incidence and prevalence of these illnesses. Diabetes is a serious, chronic disorder that can significantly affect people’s lives, wellbeing, and families all around the world. According to IDF, in 2021, there were 537 million diabetics worldwide between the ages of 20 and 79.

CLIA defines waived tests as straightforward laboratory investigations and procedures with a very low chance of producing an erroneous result. In addition to approving manufacturer petitions for test system waivers, the Food and Drug Administration (FDA) determines what standards testing must follow in terms of being simple and error prone. The Binx health io CT/NG test, a molecular platform used to detect STDs such as chlamydia and gonorrhea at the point of treatment, acquired a CLIA waiver from the US FDA in April 2021, according to a statement released at the time

Stringent and Time-Consuming Regulatory Policies Likely to Challenge Market Growth
The complicated FDA regulations and CLIA laboratory standards present manufacturers with some regulatory challenges despite the rising demand for POC equipment (for the premarket approval of POC testing kits). Manufacturers must provide performance data to the FDA for any new POC equipment to be approved in the United States. This should show that people and healthcare professionals can use these tools and get outcomes that are comparable to those of clinical laboratory tests. For in vitro diagnostic (IVD) equipment as opposed to non-IVD ones, the amount of examination is also rather exceptional. For instance, the FDA typically waits until the intended application, conditions for usage, target patient demographic, and test performance characteristics remain intact before re-examining approved prescription non-IVD devices for use in new situations. Though under this rule POC devices are not covered.

What Questions Should You Ask before Buying a Market Research Report?
• How is the point of care diagnostics market evolving?
• What is driving and restraining the point of care diagnostics market?
• How will each point of care diagnostic submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each point of care diagnostics submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading point of care diagnostics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the point of care diagnostics projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of point of care diagnostics projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the point of care diagnostics market?
• Where is the point of care diagnostics market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the point of care diagnostics market today, and over the next 10 years:
• Our 352-page report provides 158 tables, 225 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the point of care diagnostics market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising point of care diagnostics prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Product
• Glucose Monitoring
• Cardiometabolic Monitoring
• Infectious Disease Testing
• Coagulation Monitoring
• Pregnancy & Fertility Testing
• Tumor/Cancer Marker Testing
• Urinalysis Testing
• Cholesterol Testing
• Hematology Testing
• Drugs-of-abuse Testing
• Fecal Occult Testing
• Other POC Products

Mode
• Prescription-based
• OTC

Sample
• Blood
• Nasal and Oropharyngeal Swabs
• Urine
• Other

Platform
• Lateral Flow Assay
• Dipstick
• Microfluidics
• Molecular diagnostics
• Immunoassay

End User
• Clinics
• Hospitals
• Home Care Setting
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 18 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Point of Care Diagnostics Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• Abbott
• AccuBioTech Co., Ltd
• BD
• bioMerieux SA
• Chembio Diagnostics, Inc.
• Danaher
• EKF Diagnostics
• F. Hoffmann-La Roche Ltd
• Fluxergy
• LumiraDx
• Meridian Bioscience
• Nipro Europe Group Companies
• Nova Biomedical
• Orasure Technologies, Inc.
• PTS Diagnostics
• Qiagen
• Quidel Corporation
• Response Biomedical
• Sekisui Diagnostics
• Siemens Healthcare GmbH
• Spectral Medical Inc.
• Thermo Fisher Scientific Inc.
• Trinity Biotech Ireland
• Trividia Health, Inc.
• Werfen

Overall world revenue for Point of Care Diagnostics Market, 2023 to 2033 in terms of value the market will surpass US$43 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Point of care diagnostics Market, 2023 to 2033 report help you?
In summary, our 350+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Point of Care Diagnostics Market, 2023 to 2033 Market, with forecasts for product, mode, sample, platform, end user, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 18 key national markets – See forecasts for the Point of Care Diagnostics Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, Spain, Netherlands, China, India, Japan, Australia, South Korea, Brazil, GCC, and South Africa among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 25 of the major companies involved in the Point of Care Diagnostics Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Point of Care Diagnostics Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

■ 英語タイトル：Neurostimulation Devices Market Report 2023-2033 : Forecasts by Product (Deep Brain Stimulator, Gastric Electric Stimulator, Spinal Cord Stimulator, Sacral Nerve Stimulator, Vagus Nerve Stimulator, Transcutaneous Electrical Nerve Stimulation (TENS), Others), by Application (Pain Management, Epilepsy, Essential Tremor, Urinary and Faecal Incontinence, Depression, Dystonia, Gastroparesis, Parkinson’s Disease, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

■ 発行会社/調査会社：visiongain ■ 商品コード：VGA23FB013 ■ 発行日：2022年12月16日 ■ 調査対象地域：グローバル ■ 産業分野：医薬品 ■ ページ数：250 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後24時間以内）

The Neurostimulation Devices Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Favourable Regulatory and Reimbursement Scenario will Accelerate Neurostimulation Devices Market Growth
Presence of regulatory bodies such as MHRA and NICE for clinical and safety guidelines and enabling regulatory approval of neurostimulation devices under Class III devices will favour industry growth in the future. Growing focus of regulatory authorities in addressing the need for effective drug development for neurological disorders will accelerate business growth. For instance, Stimwave Technologies was granted the authorization to decide on the reimbursement with healthcare insurers over and above of the DRG payment limits for its chronic pain management products.

Complications Associated with Usage of Neurostimulation Devices
The complications in neurostimulation devices are majorly categorized into hardware complications, biological complications, and programming or therapy-related complications. Some of the hardware-related complications include battery depletion, flipping, lead migration, and recharging difficulties. Biological complications include the pain related to device components, wound infections, skin erosion, complications related to device removal, and accidental dural puncture. Programming related complications include loss of paranesthesia or painful paranesthesia. Complications related to programming are not very frequent, however it could result in device removal due to therapy failure. These aforementioned complications act as challenges in the adoption of neurostimulation devices, thereby restraining the growth of the market.

Lack of Skilled Healthcare Practitioners
The inadequate number of healthcare practitioners with the required skills to manage and treat neurological diseases will hamper industry growth over the coming years. Treatment and assessment are required to support diagnosis in a few cases. In most of cases, individual test results need to be interpreted carefully that requires skilled expertise. In most of the low and middle-income countries, access to healthcare services is challenging due to financial constraints, there is a shortage of skilled nurses and doctors, neurologists are rare, and neurological diagnostic services are not present. Even when neurological diseases are diagnosed, lack of patient information, and usage of traditional medicine delay the initiation of treatment.

What Questions Should You Ask before Buying a Market Research Report?
• How is the Neurostimulation Devices Market evolving?
• What is driving and restraining the Neurostimulation Devices Market?
• How will each Neurostimulation Devices submarket grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each Neurostimulation Devices submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading Neurostimulation Devices Markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the neurostimulation devices development projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of neurostimulation devices development projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Neurostimulation Devices Market?
• Where is the Neurostimulation Devices Market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Neurostimulation Devices Market today, and over the next 10 years:
• Our 250-page report provides 111 tables and 139 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Neurostimulation Devices Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising neurostimulation devices prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

By Product
• Deep Brain Stimulator
• Gastric Electric Stimulator
• Spinal Cord Stimulator
• Sacral Nerve Stimulator
• Vagus Nerve Stimulator
• Transcutaneous Electrical Nerve Stimulation
• Others

By Application
• Pain Management
• Epilepsy
• Essential Tremor
• Urinary and Fecal Incontinence
• Depression
• Dystonia
• Gastroparesis
• Parkinson’s Disease
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 16 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Neurostimulation Devices Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• Abbott Laboratories
• Advanced Bionics AG (Sonova)
• Boston Scientific Corporation
• BrainCo, Inc
• Cochlear Limited
• ElectroCore Inc.
• Helbling Holding AG
• Innovative Health Solutions, Inc.
• LivaNova PLC
• Medtronic
• MicroTransponder
• Neuronetics, Inc.
• Nihon Kohden Corporation
• Natus medical Incorporated
• Parasym Ltd.
• Synapse Biomedical Inc
• tVNS Technologies GmbH (Cerbomed)

Overall world revenue for Neurostimulation Devices Market, 2023 to 2033 in terms of value the market will surpass US$9,000 million in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Neurostimulation Devices Market, 2023 to 2033 report help you?
In summary, our 250-page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Neurostimulation Devices Market, 2023 to 2033 Market, with forecasts for Type of Product, Type of Application, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 16 key national markets – See forecasts for the Neurostimulation Devices Market, 2023 to 2033 market in North America, Europe, Asia-Pacific and Latin America and Middle East and Africa. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles of the major companies involved in the Neurostimulation Devices Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Neurostimulation Devices Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

■ 英語タイトル：Monoclonal Antibody Discovery and Analysis Market Report 2022-2032 : Forecasts by Business Type (Instruments Manufacturing, Services & Solutions, Ancillary Kits), by Application (Therapeutic Antibody Discovery, Critical Reagent Antibody Discovery, Biomarker and Diagnostic Antibody Discovery, Research Antibody Discovery), by Platform (Hybridoma, Humanization, Phage Display, Yeast Display, Transgenic Rodents), by Type (Antigen Development, Monoclonal Antibody Discovery, Monoclonal Antibody Manufacturing, Polyclonal Antibodies, Label-free Kinetics Analysis, Cell Banking) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

■ 発行会社/調査会社：visiongain ■ 商品コード：VGA23FB009 ■ 発行日：2022年12月16日 ■ 調査対象地域：グローバル ■ 産業分野：医薬品 ■ ページ数：437 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後24時間以内）

The Monoclonal Antibody Discovery and Analysis Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Growing Demand for Monoclonal Antibodies for Cancer Treatments
Monoclonal antibodies have demonstrated anticancer efficacy in a variety of cancers, thus they are not necessary for cancer therapy. Most toxicities, including fever, nausea, fatigue, changes in blood pressure, and bronchospasm, are self-limiting. The efficacy and timeliness of antibody-based diagnostic tests for a variety of disorders have both been enhanced by monoclonal antibodies. Clinical studies for more than 250 therapeutic monoclonal antibodies are now being conducted. These antibodies are used to treat cancer, autoimmune disorders, infectious diseases, and transplant patients. Inadequate effector functions, immunogenicity, and problems with pharmacokinetics have all been addressed through chimerization and humanization. As of November 1, 2021, 11 antibody treatments had been given first clearance for usage in either the European Union or the United States: Therapeutic antibodies will unavoidably continue to be a key component of drug research for many years to come. Regardless of the particular path used to produce the next generation of monoclonal antibody therapies, this is true.

What Questions Should You Ask before Buying a Market Research Report?
• How is the monoclonal antibody discovery and analysis market evolving?
• What is driving and restraining the monoclonal antibody discovery and analysis market?
• How will each monoclonal antibody discovery and analysis submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each monoclonal antibody discovery and analysis submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading monoclonal antibody discovery and analysis markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the monoclonal antibody discovery and analysis projects for these leading companies?
• How will the industry evolve during the period between 2020 and 2032? What are the implications of monoclonal antibody discovery and analysis projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the monoclonal antibody discovery and analysis market?
• Where is the monoclonal antibody discovery and analysis market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the monoclonal antibody discovery and analysis market today, and over the next 10 years:
• Our 437-page report provides 168 tables and 183 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the monoclonal antibody discovery and analysis market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising monoclonal antibody discovery and analysis prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Business Type
• Instruments Manufacturing
• Services & Solutions
• Ancillary Kits

Application
• Therapeutic Antibody Discovery
• Critical Reagent Antibody Discovery
• Biomarker and Diagnostic Antibody Discovery
• Research Antibody Discovery

Platform
• Hybridoma
• Humanization
• Phage Display
• Yeast Display
• Transgenic Rodents

Type
• Antigen Development
• Monoclonal Antibody Discovery
• Monoclonal Antibody Manufacturing
• Polyclonal Antibodies
• Label-free Kinetics Analysis
• Cell Banking

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• Spain
• United Kingdom
• France
• Italy
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Middle East & Africa
• Turkey
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Latin America
• Brazil
• Mexico
• Rest of Latin America

The report also includes profiles and for some of the leading companies in the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• AbbVie Inc.
• Amgen Inc.
• Amneal Pharmaceutical LLC
• AstraZeneca
• Bayer AG
• BIOGEN
• Bristol- Myers Squibb company
• Eisai Co. Ltd
• Eli Lilly and Company
• F. Hoffman-La Roche Ltd.
• GlaxoSmithKline plc
• Johnson & Johnson Ltd.
• Lupin Limited
• Viatris Inc.
• Novartis AG
• Pfizer Inc.
• Regeneron Pharmaceuticals Inc.
• Sanofi S.A.
• Teva Pharmaceutical Industries Ltd.
• Zydus Lifesciences Limited

Overall world revenue for Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032 in terms of value the market will surpass US$5,610 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032 report help you?
In summary, our 430+ page report provides you with the following knowledge:

• Revenue forecasts to 2032 for Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032 Market, with forecasts for business type, platform, type, application and company size, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2032 for four regional and 20 key national markets – See forecasts for the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Middle East & Africa and Latin America. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 20 of the major companies involved in the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Monoclonal Antibody Discovery and Analysis Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

■ 英語タイトル：Infectious Disease Diagnostics Market Report 2022-2032 : Forecasts by Product (Instrument, Reagents, Kits, & Consumables, Software & Services), by Type of Testing (Laboratory Testing and POC Testing), by Technology (Immunodiagnostics, Polymerase Chain Reaction (PCR), DNA Sequencing And Next-Generation Sequencing (NGS), Clinical Microbiology, Other), by Application (COVID-19, Human Immunodeficiency Virus (HIV), Healthcare-Associated Infections (HAIs), Hepatitis, Human Papillomavirus (HPV), Tuberculosis (TB), Influenza, Other), by End-user (Diagnostic Laboratories, Hospitals & Clinics, Research Institutes, Home Care Settings, Other) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

■ 発行会社/調査会社：visiongain ■ 商品コード：VGA23FB008 ■ 発行日：2022年12月16日 ■ 調査対象地域：グローバル ■ 産業分野：医薬品 ■ ページ数：325 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後24時間以内）

The Infectious Disease Diagnostics Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Growing Prevalence of Infectious Diseases, And Shift in Focus from Centralized Laboratories to Decentralized POC Testing Are Driving the Market Growth
Growing prevalence of infectious diseases is anticipated to drive the growth of the infectious disease diagnostics market over the forecast period. For instance, on February 23, 2020, there were 76,936 reported cases in mainland China and 1,875 cases of coronavirus disease 2019 in locations outside mainland China and the number of associated deaths was 2,462.

According to The Joint United Nations Programme on HIV/AIDS (UNAIDS), 37.7 million individuals were HIV positive in 2020, out of which 36 million were adults and 1.7 million were children between the ages of 0 and 14. Furthermore, more than half (53%) were females. 1.5 million new HIV cases were recorded in 2020 worldwide. Further, Hepatitis is a viral infection that results in liver inflammation. Hepatitis viruses come in five primary strains: A, B, C, D, and E. As per the World Health Organization (WHO), about 58 million individuals worldwide have chronic hepatitis C virus infection, and 1.5 million new infections occur each year.

According to WHO, After COVID-19, tuberculosis (TB) is the second most common infectious disease in the world and the thirteenth leading cause of death overall. As per WHO, 1.5 million deaths were caused due to TB in 2020 (including 214,000 people affected by HIV). WHO anticipated that 10 million individuals, including 1.1 million children, 3.3 million women, and 5.6 million men, would be affected by TB worldwide in 2020. All countries and age ranges are affected by TB. In addition, 30 countries with heavy TB burdens accounted for 86% of new TB cases in 2020. Two-thirds of the total is made up of eight countries, with India topping the list, then China, the Philippines, Nigeria, Pakistan, Indonesia, Bangladesh, and South Africa.

Moreover, the growing prevalence of healthcare-acquired infections (HAIs) globally. For instance, according to the Centers for Disease Control (CDC), HAIs alone in American hospitals are considered to be responsible for 1.7 million infections and 99,000 associated deaths per year. Of these infections, urinary tract infections make up 32% of all healthcare-acquired infections, followed by surgical site infections (22%), pneumonia (15%), and bloodstream infections (14%).

Growing prevalence of infectious diseases in developed and emerging nations will positively impact the growth of the infectious disease diagnostics market. The diagnosis and management of these diseases are key responsible factors for the rising number of prescriptions for diagnostic tests for infectious diseases. Large-scale population-based diagnostic testing is required for the prevention and control measures of COVID-19.

What Questions Should You Ask before Buying a Market Research Report?
• How is the infectious disease diagnostics market evolving?
• What is driving and restraining the infectious disease diagnostics market?
• How will each infectious disease diagnostics submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each infectious disease diagnostics submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading infectious disease diagnostics markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the infectious disease diagnostics research projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of infectious disease diagnostics projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the infectious disease diagnostics market?
• Where is the infectious disease diagnostics market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Infectious Disease Diagnostics Market today, and over the next 10 years:
• Our 32-page report provides 120 tables and 201 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Infectious Disease Diagnostics Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising infectious disease diagnostics prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Product
• Instrument
• Reagents, Kits, and Consumables
• Software & Services

Type of Testing
• Laboratory Testing
• POC Testing

Technology
• Immunodiagnostics
• Polymerase Chain Reaction (PCR)
– Real-time PCR/qPCR
– Reverse Transcriptase PCR (RT-PCR)
– Multiplex PCR
– Others
• DNA Sequencing and Next-Generation Sequencing (NGS)
• Clinical Microbiology
• Other technologies

Application
• COVID-19
• Human Immunodeficiency Virus (HIV)
• Healthcare-Associated Infections (HAIs)
• Hepatitis
• Human Papillomavirus (HPV)
• Tuberculosis (TB)
• Influenza
• Other Infectious Diseases

Application
• Diagnostic Laboratories
• Hospitals & Clinics
• Research Institutes
• Home Care Settings
• Other End Users

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 19 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Infectious Disease Diagnostics Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• Abbott
• Alere Inc.
• BioMérieux SA
• Becton, Dickinson and Company
• Cepheid, Inc.
• Co-Diagnostics
• Chembio Diagnostic Systems
• Danaher Corporation
• DiaSorin S.p.A.
• ELITechGroup
• Epitope Diagnostics
• F. Hoffmann-La Roche
• Hologic, Inc.
• Grifols S.A.
• Genetic Signatures Ltd.
• InBios International
• Meridian Bioscience
• Ortho Clinical Diagnostics Holdings plc
• OraSure Technologies
• PerkinElmer Inc.
• Siemens Healthineers
• Sysmex Corporation
• Thermo Fisher Scientific
• Trinity Biotech Plc.
• Trivitron Healthcare
• Uniogen Oy
• Vela Diagnostics
• Meril Life Sciences Pvt. Ltd
• Quidel Corporation.

Overall world revenue for Infectious Disease Diagnostics Market, 2022 to 2032 in terms of value the market will surpass US$ 29,940.3 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Infectious Disease Diagnostics Market, 2022 to 2032 report help you?
In summary, our 320+ page report provides you with the following knowledge:

• Revenue forecasts to 2032 for Infectious Disease Diagnostics Market, 2022 to 2032 Market, with forecasts for type and company size, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2032 for five regional and 19 key national markets – See forecasts for the Infectious Disease Diagnostics Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 10 of the major companies involved in the Infectious Disease Diagnostics Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Infectious Disease Diagnostics Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

■ 英語タイトル：Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2022-2032 : Forecasts by Molecule Type (Small Molecule, Large Molecule), by Type (Monoclonal Antibodies (mAbs), Cytokines, Insulin, Peptide Hormones, Vaccines, Immunoglobulins, Blood Factors, Peptide Antibiotics, Others), by Application (Cancer, Diabetes, Cardiovascular Diseases, CNS, Infectious, Others), by Container Type (Bottles, Ampoules, Vials, Pre-filled Syringes, Bags), by Route of Administration (Subcutaneous (SC), Intravenous (IV), Intramuscular (IM), Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

■ 発行会社/調査会社：visiongain ■ 商品コード：VGA23FB006 ■ 発行日：2022年12月16日 ■ 調査対象地域：グローバル ■ 産業分野：医薬品 ■ ページ数：357 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後24時間以内）

The Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Rising Demand for Outsourcing Drug Manufacturing by Pharmaceutical Companies to Boost Market Growth
Over the last few decades, contract manufacturing organisations (CMOs) have evolved as a viable alternative to pharmaceutical businesses’ in-house research and production departments. Contract manufacturing organisations (CMOs) are proven to be a successful business model as they become more integrated into pharmaceutical firms’ value chains. Despite the fact that the sector as a whole is expanding, many CMOs are encountering new obstacles. As a result of growing expenses, constantly improving technology, and a surge in mergers and acquisitions, competition in this sector has intensified. As a result of these considerations, organisations must decide what actions they might take to defend or improve their position.

Manufacturing costs are much lower in the Asia-Pacific area than in North America and Europe, and favourable laws are fuelling the rise of the CMO business. Despite the fact that API manufacturing services have mostly shifted to China and India, the United States remains the major site for pharmaceutical development outsourcing. Several reasons contribute to this predicament, including the abundance of funding and the concentration of pharmaceutical research hubs in universities. Pharmaceutical development in poor countries is also unfavourable owing to quality difficulties, logistical constraints, and legal challenges.

Market Growth is Hindered by Growing Competition from Small Manufacturers
The market’s discontinuance is considered in the perspective of the whole evaluation process for product lifespan and market viability. Drug discontinuation is defined as authorised products that are removed from the market or withdrawn for reasons other than safety or efficacy and are never again discontinued, marketed, exported, or used in the military. The possibility for a pharmaceutical corporation to pull a medicine from the market can have serious effects, including financial losses, loss of goodwill, and disrupted therapeutic research.

The consumer product literature contains well-developed dominating pricing methods, particularly skimming and penetration pricing. Pharmaceutical items use the same market-dynamic pricing mechanisms as other products. According to the current market study, the primary factor determining a product’s pricing is a larger therapeutic benefit. The greater the clinical benefit over previously accessible medications on the market, the higher the initial price of the product. If the sterile injectables medication product’s life cycle was not extended, this incident might result in significant losses for the corporation and, finally, product termination.

What Questions Should You Ask before Buying a Market Research Report?
• How is the CMO of Sterile Injectable Drugs market evolving?
• What is driving and restraining the CMO of Sterile Injectable Drugs market?
• How will each CMO of Sterile Injectable Drugs submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each CMO of Sterile Injectable Drugs submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading CMO of Sterile Injectable Drugs markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the CMO of Sterile Injectable Drugs projects for these leading companies?
• How will the industry evolve during the period between 2022 and 2032? What are the implications of CMO of Sterile Injectable Drugs projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the CMO of Sterile Injectable Drugs market?
• Where is the CMO of Sterile Injectable Drugs market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the CMO of Sterile Injectable Drugs market today, and over the next 10 years:
• Our 357-page report provides 116 tables and 175 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the CMO of Sterile Injectable Drugs market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising CMO of Sterile Injectable Drugs prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Molecule Type
• Small Molecule
• Large Molecule

Type
• Monoclonal Antibodies (mAbs)
• Cytokines
• Insulin
• Peptide Hormones
• Vaccines
• Immunoglobulins
• Blood Factors
• Peptide Antibiotics
• Others

Application
• Cancer
• Diabetes
• Cardiovascular diseases
• CNS
• Infectious
• Others

Container Type
• Bottles
• Ampoules
• Vials
• Prefilled syringes
• Bags

Route of Administration
• Subcutaneous (SC)
• Intravenous (IV)
• Intramuscular (IM)
• Others

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 18 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• Adare Pharma Solutions
• Aenova Group
• Almac Group
• Avara Pharmaceutical Services, Inc.
• Baxter International Inc.
• Boehringer Ingelheim International GmbH
• Catalent, Inc.
• CordenPharma
• Eli Lilly and Company
• Evonik Industries AG
• F. Hoffmann-La Roche Ltd
• FAMAR Health Care Services
• Fresenius Kabi Ag
• Grifols SA
• Hikma Pharmaceuticals PLC
• Jubilant Pharmova Limited
• Lonza
• Nexus Pharmaceuticals, Inc.
• Patheon, Inc. (Thermo Fischer)
• Pfizer CentreOne
• Recipharm AB
• Siegfried Holding AG

Overall world revenue for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032 in terms of value the market will surpass US$22,300.0 million in 2023, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032 report help you?
In summary, our 370+ page report provides you with the following knowledge:

• Revenue forecasts to 2032 for Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032 Market, with forecasts for molecule type, type, application, container type, and route of administration, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2032 for five regional and 18 key national markets – See forecasts for the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032 market in North America, Europe, Asia-Pacific, LA, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 22 of the major companies involved in the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.

■ 英語タイトル：Cardiovascular Devices Market Report 2023-2033 : Forecasts by Disease (Hypertension, Atrial Fibrillation, Chronic Ischemic Heart Diseases, Stroke, Heart Failure, Other), by Type (Diagnostic and Monitoring Devices, Therapeutic, Surgical Devices), by End-users (Hospitals, Diagnostic Laboratories, Home and Ambulatory Care, Research Laboratories) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

■ 発行会社/調査会社：visiongain ■ 商品コード：VGA23FB012 ■ 発行日：2022年12月14日 ■ 調査対象地域：グローバル ■ 産業分野：医薬品 ■ ページ数：273 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後24時間以内）

The Cardiovascular Devices Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Growth Potential in Emerging Economies
The high occurrence of diabetes along with the large geriatric population in these emerging economies such as Japan, India, China, & Brazil provides substantial development opportunities for the cardiovascular devices market. As per the World Health Organization over 18 million people die due to CVDs each year. Of these deaths, over three-fourths deaths are attributed to heart attack and stroke. Besides, approximately two-thirds of CVD deaths take place in low-and middle-income nations where high blood pressure (BP) is amongst the most important risk factors. People at risk of CVD may exhibit high BP, glucose, and lipid along with overweight and obesity. To identify those at the maximum risk of CVDs along with to ensure they receive suitable treatment is expected to prevent premature deaths. In Brazil, non-communicable diseases (NCDs), accounted for approximately three-fourths of total deaths. Therefore, potential across emerging nations is projected to provide lucrative growth opportunities for the regional market players.

Growing Availability of Efficient Devices
The cardiovascular devices market is expected to witness exponential growth in the future with the high adoption of cutting-edge technologies to serve the rising disease burden. In addition, there has been an increase in the incidence of heart diseases globally, which leads to the demand for efficient and state-of-the-art heart devices. The availability of cutting-edge devices has led to the implementation of these devices in developed nations. Besides, there has been a rise in government initiatives along with funding for research and development activities. Further, investors are focusing on escalating the availability of advanced and economical cardiovascular devices in emerging markets. For instance, in 2020, AliveCor, one of the leading enterprise cardiac solution and AI-based ECG technology providers, launched KardiaMobile device in Mexico. This device is used to store, record, and transfer single-channel electrocardiogram rhythms from the patients. This launch was done through a partnership between AliveCor and Mexico-based Inpharamo, a medical solutions company. Hence, growth in accessibility of efficient devices is projected to offer lucrative growth prospects over the forecast period.

What Questions Should You Ask before Buying a Market Research Report?
• How is the cardiovascular devices market evolving?
• What is driving and restraining the cardiovascular devices market?
• How will each cardiovascular devices submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each cardiovascular devices submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading cardiovascular devices markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the cardiovascular devices projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of
cardiovascular devices projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the cardiovascular devices market?
• Where is the cardiovascular devices market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the cardiovascular devices market today, and over the next 10 years:
• Our 273-page report provides 112 tables and 170 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the cardiovascular devices market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, and restraints), Porter’s Five Forces Analysis, PEST Analysis and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Disease
• Hypertension
• Atrial Fibrillation
• Chronic Ischemic Heart Diseases
• Stroke
• Heart Failure
• Other Diseases

Type
• Diagnostic and Monitoring Devices
• Therapeutic and Surgical Devices

End-users
• Hospitals
• Diagnostic Laboratories
• Home and Ambulatory Care
• Research Laboratories

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 21 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Italy
• Spain
• Russia
• Rest of Europe

Asia Pacific
• Japan
• China
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Cardiovascular Devices Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• Abbott
• B. Braun SE
• BD
• BIOTRONIK SE & CO. KG
• Boston Scientific Corporation
• Canon Medical Systems Corporation
• Cardinal Health
• Cook Group
• Edwards Lifesciences Corporation
• GE Healthcare
• Johnson & Johnson Services, Inc.
• Koninklijke Philips N.V.
• LivaNova PLC
• Medtronic plc
• Siemens Healthcare GmbH
• Terumo Corporation
• W. L. Gore & Associates, Inc.

Overall world revenue for Cardiovascular Devices Market, 2023 to 2033 in terms of value the market will surpass US$65 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Cardiovascular Devices Market, 2023 to 2033 report help you?
In summary, our 270+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Cardiovascular Devices Market, 2023 to 2033 Market, with forecasts for Disease, Type, and End-users, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 21 key national markets – See forecasts for the Cardiovascular Devices Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 17 of the major companies involved in the Cardiovascular Devices Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Cardiovascular Devices Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

■ 英語タイトル：Respiratory Inhalers Market Report 2023-2033 : Forecasts by Product Type (Standard Pressurised Metered-Dose Inhalers, Pressurised Metered-dose Inhalers, Metered-Dose Inhaler with a Spacer, Dry Powder Inhalers, Soft Mist Inhalers, Others), by Drug Class (ICS, SABA+ICS, SABA, LABA, LAMA, ULABA, SABA+SAMA, LABA+LAMA+ICS, SAMA, Others), by Mode of Operation (Manually Operated Inhaler Devices, Digitally Operated Inhaler Devices, Others), by Indication (Asthma, Chronic Obstructive Pulmonary Disease, Pulmonary Arterial Hypertension, Others) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

■ 発行会社/調査会社：visiongain ■ 商品コード：VGA23FB021 ■ 発行日：2022年12月13日 ■ 調査対象地域：グローバル ■ 産業分野：医薬品 ■ ページ数：354 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後24時間以内）

The Respiratory Inhalers Market Report 2023-2033: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Growing R&D Expenditure by Pharmaceutical and Biotechnology Companies Driving Market Growth
As the demand for greater precision in drug delivery grows, respiratory inhaler devices, particularly among asthmatics and those suffering from chronic obstructive pulmonary disease, are becoming more popular. Because they have a decreased degree of immunity to chronic and pulmonary diseases, an increasing percentage of senior people utilise inhalers. Respiratory inhalers include complementary spacers or holding chambers to reduce the number of debris deposited in the mouth and throat. The market for respiratory products is expected to grow even more in light of the proposed shift to home healthcare.

One of the major digital platforms on which pharma and digital companies collaborate for the management of respiratory diseases is the smart inhaler market. In recent years, government organizations have been concerned about the rising death rates associated with respiratory diseases such as asthma and COPD. Government and regulatory agencies have implemented new guidelines in recent years that will significantly impact the market growth of smart inhalers. Increasing numbers of organizations are integrating digital technologies into their devices in an effort to improve medication management efficiency. The HeroTracker Sense application was launched by Aptar Pharma in April 2023, for example. Pressurized metered dose inhaler (pMDI) can now be converted into a smart connected health device through the use of this new digital respiratory health solution.

High Cost of Inhalers Likely to Challenge Market Growth
Despite the increased prevalence of asthma worldwide, including in emerging markets such as Asia and developed areas such as North America, several barriers to the acceptance of these therapies exist. Inhalers are frequently regarded as the primary treatment for asthma, which is one of the major issues limiting market growth. According to the NCBI study, the CDC will spend approximately 49 billion in 2020, with Medicare covering only 51% of the COPD cost burden. As a result, the price of Advair, a critical asthma medication, has risen to US$648.8 in 2023, up from US$496.0 in 2013.

In addition to the high cost of drugs, underdiagnosis of asthma has been a key issue restricting market expansion. Asthma underdiagnosis leads to lower clinical outcomes for people who are unable to take the right asthma medicines to treat their medical condition. A lack of awareness and perception of asthma in the community, poor access to health care, strained health systems, the absence of diagnostic tests, including spirometry, a lack of training among health care providers, and a lack of non-implementation of asthma guidelines are all factors that contribute to underdiagnosis of asthma.

What Questions Should You Ask before Buying a Market Research Report?
• How is the respiratory inhalers market evolving?
• What is driving and restraining the respiratory inhalers market?
• How will each respiratory inhalers submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2033?
• How will the market shares for each respiratory inhalers submarket develop from 2023 to 2033?
• What will be the main driver for the overall market from 2023 to 2033?
• Will leading respiratory inhalers markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2033 and which geographical region will lead the market in 2033?
• Who are the leading players and what are their prospects over the forecast period?
• What are the respiratory inhalers projects for these leading companies?
• How will the industry evolve during the period between 2023 and 2033? What are the implications of respiratory inhalers projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the respiratory inhalers market?
• Where is the respiratory inhalers market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the respiratory inhalers market today, and over the next 10 years:
• Our 354-page report provides 126 tables and 184 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the respiratory inhalers market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2033 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2033, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising respiratory inhalers prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Product Outlook
• Standard Pressurized Metered-Dose Inhalers
• Pressurized Metered-dose Inhalers (pMDI)
• Metered-Dose Inhaler with a Spacer
• Dry Powder Inhalers
• Soft Mist Inhalers
• Other Inhaler Type

Drug Class
• ICS
• SABA+ICS
• SABA
• LABA
• LAMA
• ULABA
• SABA+SAMA
• LABA+LAMA+ICS
• SAMA
• Other Class

Mode of Operation
• Manually Operated Inhaler Devices
• Digitally Operated Inhaler Devices
• Other Mode Of Operation

Indication
• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Pulmonary Arterial Hypertension (PAH)
• Others Respiratory Disease

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 18 leading national markets:

North America
• U.S.
• Canada

Europe
• Germany
• UK
• France
• Spain
• Italy
• Russia
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America

MEA
• GCC
• South Africa
• Rest of MEA

The report also includes profiles and for some of the leading companies in the Respiratory Inhalers Market, 2023 to 2033, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• 3M Health Care
• AptarGroup, Inc.
• AstraZeneca
• Boehringer Ingelheim International GmbH
• Cipla Inc.
• GF Health Products, Inc.
• GSK plc
• Koninklijke Philips N.V.
• Medisana GmbH
• Merck & Co., Inc.
• Novartis AG
• OMRON Corporation
• Recipharm AB
• Sunovion Pharmaceuticals Inc.
• Teva Pharmaceutical Industries Ltd.

Overall world revenue for Respiratory Inhalers Market, 2023 to 2033 in terms of value the market will surpass US$45.0 billion in 2023, our work calculates. We predict strong revenue growth through to 2033. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Respiratory Inhalers Market, 2023 to 2033 report help you?
In summary, our 350+ page report provides you with the following knowledge:

• Revenue forecasts to 2033 for Respiratory Inhalers Market, 2023 to 2033 Market, with forecasts for product type, drug class, mode of operation, and indication, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2033 for five regional and 18 key national markets – See forecasts for the Respiratory Inhalers Market, 2023 to 2033 market in North America, Europe, Asia-Pacific, LA, and MEA. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 15 of the major companies involved in the Respiratory Inhalers Market, 2023 to 2033.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Respiratory Inhalers Market, 2023 to 2033, market-leading companies. You will find data, trends and predictions.

■ 英語タイトル：Protein Expression, Purification and Isolation Technology Market Report 2022-2032 : Forecasts by Technology (Protein Expression Technology (Cell-Free Expression, Bacterial Expression, Yeast Expression, Algal Expression, Insect Expression, Others), Protein Purification & Isolation Technology (Ultrafiltration, Precipitation, Chromatography, Electrophoresis, Western Blotting, Others)), by Application (Therapeutic, Industrial, Research), by End-user (Academia, Biotechnology and Pharmaceutical Companies, Contract Research Organisations) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis

■ 発行会社/調査会社：visiongain ■ 商品コード：VGA23FB014 ■ 発行日：2022年12月12日 ■ 調査対象地域：グローバル ■ 産業分野：医薬品 ■ ページ数：261 ■ レポート言語：英語 ■ レポート形式：PDF ■ 納品方式：Eメール（受注後24時間以内）

The Protein Expression, Purification and Isolation Technology Market Report 2022-2032: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.

Factors Such as increase in investment in Pharmaceutical and Biotechnological R&D
Rising R&D investments by pharmaceutical companies are expected to drive the market. Protein expression has several advantages, including a shorter expression time and structural modification, which contributes to the growing demand for it in the development of treatments for emerging diseases.

Investments in research and development have increased, resulting in the introduction of new protein therapeutics, which has significantly contributed to the market’s growth and development. The development of new protein therapeutics to address unmet medical needs is one of the key value drivers for research-based pharmaceutical companies. Rise in R&D funding coupled with expansion of manufacturing sites are major factors driving the market growth.

Market players are found actively investing in research and development, which is fuelling the growth of the market. For instance, recently, in October 2019, the Bio-Techne company invested up to US$ 50 million in a new plant for recombinant proteins. The setup of new plant has, is anticipated to fuel in market growth.

High Cost of Protein Expression Systems to impede the market growth
A factor impeding market growth is the high cost of protein expression systems, as well as competent cells and reagents required for protein expression. The amount of protein required for large-scale applications such as enzyme, antibody, or vaccine production is significant. In such cases, the system in which the protein is expressed must be easy to culture and maintain, grow rapidly, and produce large amounts of protein. Moreover, mammalian proteins also undergo various post-translational modifications. Protein expression systems overcome these difficulties and make the process easier, but these systems are currently not economical.

What Questions Should You Ask before Buying a Market Research Report?
• How is the Protein Expression, Purification and Isolation Technology market evolving?
• What is driving and restraining the Protein Expression, Purification and Isolation Technology market?
• How will each Protein Expression, Purification and Isolation Technology submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2032?
• How will the market shares for each Protein Expression, Purification and Isolation Technology submarket develop from 2022 to 2032?
• What will be the main driver for the overall market from 2022 to 2032?
• Will leading Protein Expression, Purification and Isolation Technology markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2032 and which geographical region will lead the market in 2032?
• Who are the leading players and what are their prospects over the forecast period?
• What are the Protein Expression, Purification and Isolation Technology projects for these leading companies?
• How will the industry evolve during the period between 2020 and 2032? What are the implications of Protein Expression, Purification and Isolation Technology projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the Protein Expression, Purification and Isolation Technology market?
• Where is the Protein Expression, Purification and Isolation Technology market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?

You need to discover how this will impact the Protein Expression, Purification and Isolation Technology market today, and over the next 10 years:
• Our 261-page report provides 103 tables and 184 charts/graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.

This report tells you TODAY how the Protein Expression, Purification and Isolation Technology market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.

Forecasts to 2032 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2032, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising Protein Expression, Purification and Isolation Technology prices and recent developments.

This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.

Segments Covered in the Report

Technology Outlook
• Protein Expression Technology
– Cell-Free Expression
– Bacterial Expression
– Yeast Expression
– Algal Expression
– Insect Expression
– Mammalian Expression
– Others
• Protein Purification & Isolation Technology
– Ultrafiltration
– Precipitation
– Chromatography
– Electrophoresis
– Western Blotting
– Others

End User
• Academia
• Biotechnology and Pharmaceutical Companies
• Contract Research Organizations (CROs)

Application
• Therapeutic
• Industrial
• Research

In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for four regional and 20 leading national markets:

North America
• U.S.
• Canada
• Mexico

Europe
• Germany
• Spain
• United Kingdom
• France
• Italy
• Rest of Europe

Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia Pacific

LAMEA
• Brazil
• Turkey
• Saudi Arabia
• South Africa
• UAE
• Rest of Latin America

The report also includes profiles and for some of the leading companies in the Protein Expression, Purification and Isolation Technology Market, 2022 to 2032, with a focus on this segment of these companies’ operations.

Leading companies and the potential for market growth
• Agilent Technologies Inc.
• Bio-Rad Laboratories
• F. Hoffmann-La Roche Ltd.
• GE Healthcare
• Merck KGaA
• Promega Corporation
• Qiagen N.V.
• Thermo Fisher Scientific

Overall world revenue for Protein Expression, Purification and Isolation Technology Market, 2022 to 2032 in terms of value the market will surpass US$10,126.5 million in 2022, our work calculates. We predict strong revenue growth through to 2032. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.

How will the Protein Expression, Purification and Isolation Technology Market, 2022 to 2032 report help you?
In summary, our 260+ page report provides you with the following knowledge:

• Revenue forecasts to 2032 for Protein Expression, Purification and Isolation Technology Market, 2022 to 2032 Market, with forecasts for Technology, upstream, Application, type and company size, each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.

• Revenue forecasts to 2032 for four regional and 20 key national markets – See forecasts for the Protein Expression, Purification and Isolation Technology Market, 2022 to 2032 market in North America, Europe, Asia-Pacific and Latin America and Middle East and Africa. Also forecasted is the market in the US, Canada, Mexico, Brazil, Germany, France, UK, Italy, China, India, Japan, and Australia among other prominent economies.

• Prospects for established firms and those seeking to enter the market – including company profiles for 8 major companies involved in the Protein Expression, Purification and Isolation Technology Market, 2022 to 2032.

Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.

Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Our study is for everybody needing commercial analyses for the Protein Expression, Purification and Isolation Technology Market, 2022 to 2032, market-leading companies. You will find data, trends and predictions.